IPF Summit 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist (APT101) and its effects in models of acute and chronic lung injury
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
